Parihar Manish, Dodds Sherry G, Javors Marty, Strong Randy, Hasty Paul, Sharp Zelton Dave
Department of Molecular Medicine and Institute of Biotechnology, University of Texas Health San Antonio, San Antonio, TX, USA.
Greehey Children's Cancer Research Institute, University of Texas Health San Antonio, San Antonio, TX, USA.
Aging Pathobiol Ther. 2020;2(4):187-194. doi: 10.31491/apt.2020.12.039. Epub 2020 Dec 31.
mice model familial adenomatous polyposis (FAP), a disease that causes numerous colon polyps leading to colorectal cancer. We previously showed that chronic treatment of females with the anti-aging drug, rapamycin, restored a normal lifespan through reduced polyposis and anemia prevention. Lifespan extension by chronic rapamycin in wildtype UM-HET3 mice is sex-dependent with females gaining the most benefit. Whether mice have a similar sex-dependent response to chronic mTOR inhibition is not known.
To address this knowledge gap and gain deeper insight into how chronic mTOR inhibition prevents intestinal polyposis, we compared male and female mice responses to chronic treatment with a rapamycin-containing diet. Animals were fed a diet containing either 42 ppm microencapsulate rapamycin or empty capsules, one group was used to determine lifespan and a second group with similar treatment was harvested at 16 weeks of age for cross-sectional studies.
We found that the survival of males is greater than females in this setting (P < 0.0197). To explore the potential basis for this difference we analyzed factors affected by chronic rapamycin. Immunoblot assays showed that males and females exhibited approximately the same level of mTORC1 inhibition using phosphorylation of ribosomal protein S6 (rpS6) as an indirect measure. Immunohistochemistry assays of rpS6 phosphorylation showed that rapamycin reduction of mTORC1 activity was on the same level, with the most prominent difference being in intestinal crypt Paneth cells in both sexes. Chronic rapamycin also reduced crypt depths in both male and female mice (P < 0.0001), consistent with reduced crypt epithelial cell proliferation. Finally, chronic rapamycin prevented anemia equally in males and females.
In males and females, these findings link rapamycin-mediated intestinal polyposis prevention with mTORC1 inhibition in Paneth cells and concomitant reduced epithelial cell proliferation.
小鼠家族性腺瘤性息肉病(FAP)模型,该疾病会导致大量结肠息肉,进而引发结直肠癌。我们之前表明,用抗衰老药物雷帕霉素对雌性小鼠进行长期治疗,可通过减少息肉病和预防贫血来恢复正常寿命。野生型UM - HET3小鼠长期使用雷帕霉素延长寿命存在性别依赖性,雌性受益最大。尚不清楚小鼠对长期mTOR抑制是否有类似的性别依赖性反应。
为填补这一知识空白,并更深入了解长期mTOR抑制如何预防肠道息肉病,我们比较了雄性和雌性小鼠对含雷帕霉素饮食长期治疗的反应。给动物喂食含42 ppm微囊化雷帕霉素或空胶囊的饮食,一组用于确定寿命,另一组接受类似治疗,在16周龄时处死用于横断面研究。
我们发现在这种情况下雄性小鼠的存活率高于雌性(P < 0.0197)。为探究这种差异的潜在原因,我们分析了受长期雷帕霉素影响的因素。免疫印迹分析表明,以核糖体蛋白S6(rpS6)磷酸化作为间接指标,雄性和雌性小鼠的mTORC1抑制水平大致相同。rpS6磷酸化的免疫组织化学分析表明,雷帕霉素降低mTORC1活性的水平相同,最显著的差异在于两性的肠隐窝潘氏细胞。长期雷帕霉素还降低了雄性和雌性小鼠的隐窝深度(P < 0.0001),这与隐窝上皮细胞增殖减少一致。最后,长期雷帕霉素对雄性和雌性小鼠预防贫血的效果相同。
在雄性和雌性小鼠中,这些发现将雷帕霉素介导的肠道息肉病预防与潘氏细胞中的mTORC1抑制以及上皮细胞增殖减少联系起来。